Control of hematopoiesis and apoptosis in MDS: more than FLIPing the coin.
Mhyre
Andrew J
AJ
Deeg
H Joachim
HJ
D000943:Antigens, Differentiation / Q000096:biosynthesis / Q000235:genetics; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics; D001374:Azacitidine / Q000627:therapeutic use; D053446:CASP8 and FADD-Like Apoptosis Regulating Protein / Q000235:genetics / Q000378:metabolism*; D053181:Caspase 8 / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects / Q000235:genetics; D042783:Endothelial Cells / Q000378:metabolism / Q000473:pathology; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005786:Gene Expression Regulation / Q000187:drug effects / Q000235:genetics; D006410:Hematopoiesis / Q000187:drug effects / Q000235:genetics; D006412:Hematopoietic Stem Cells / Q000378:metabolism / Q000473:pathology; D006801:Humans; D000077269:Lenalidomide; D009000:Monocytes / Q000378:metabolism / Q000473:pathology; D009190:Myelodysplastic Syndromes / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics; D017154:Stromal Cells / Q000378:metabolism / Q000473:pathology; D013601:T-Lymphocytes / Q000378:metabolism / Q000473:pathology; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
D000943:Antigens, Differentiation; D000970:Antineoplastic Agents; D053446:CASP8 and FADD-Like Apoptosis Regulating Protein; D004791:Enzyme Inhibitors; D013792:Thalidomide; C505530:CASP8 protein, human; D053181:Caspase 8; D000077269:Lenalidomide; D001374:Azacitidine